IP Library Granted Patent US 10,898,523
Granted Patent B2
US 10,898,523 · App. 16/100,545 · Granted Jan 26, 2021

Methods of producing activated mesenchymal stem cells

Inventors: Yufang Shi (Belle Mead, NJ); Guangwen Ren (Piscataway, NJ); Liying Zhang (Belle Mead, NJ)
Assignee: Rutgers, The State University of New Jersey
A61K35/28A61K38/191A61K38/2006A61K38/217A61K45/06A61P37/02C12N5/0018C12N5/0607C12N5/0662C12N5/0663C12N5/0665A61K2035/122C07K14/495C07K14/50C07K14/52C07K14/525C07K14/545C07K14/56C07K14/565C07K14/57C12N2500/05C12N2501/10C12N2501/115C12N2501/15C12N2501/2301C12N2501/2317C12N2501/24C12N2501/25C12N2502/1114
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,898,523
App. No.
16/100,545
Granted
Jan 26, 2021
Kind
B2
Abstract

The present invention provides methods or kits with inflammatory cytokines to pretreat 1-ISCs to augment their immune modulatory effect, in prevention and treatment of various diseases such as multiple sclerosis, arthritis, lupus, sepsis, hepatitis, cirrhosis, Parkinson's disease, chronic infections, and GvHD. The present invention relates to novel methods for enhancing the immunosuppressive or the immune stimulatory activities of mesenchymal stem cells (JvfSCs).

Claims (9)

1. A method of cultivating a population of activated mesenchymal stem cells comprising the steps of:

(i) obtaining multipotent progenitor cells;

(ii) culturing said multipotent cells in a medium;

(iii) separating clonal mesenchymal stem cells from differentiated cells in said medium;

(iv) activating at least a subset of said separated mesenchymal stem cells with interferon gamma (IFNγ) and at least one cytokine selected from the group consisting of interleukin-1 alpha (IL-1α), interleukin-1 beta (IL-1β), Type 1 interferon α (IFN-Iα), Type 1 interferon β (IFN-Iβ), tumor necrosis factor alpha (TNFα), transforming growth factor β (TGFβ), and fibroblast growth factor (FGF), and any combinations thereof, for a sufficient period of time such that the activated mesenchymal stem cells are immunomodulatory.

2. A method of cultivating a population of activated mesenchymal stem cells comprising the steps of:

(i) culturing multipotent cells in a medium;

(ii) separating clonal mesenchymal stem cells from differentiated cells in said medium;

(iii) activating at least a subset of said separated mesenchymal stem cells with interferon gamma (IFNγ) and at least two cytokines selected from the group consisting of interleukin-1 alpha (IL-1α), interleukin-1 beta (IL-1β), Type 1 interferon α (IFN-Iα), Type 1 interferon β (IFN-Iβ), tumor necrosis factor alpha (TNFα), transforming growth factor β (TGFβ), and fibroblast growth factor (FGF), and any combinations thereof, for a sufficient period of time such that the activated mesenchymal stem cells are immunomodulatory.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 30, 2020
From: SHI, YUFANG; REN, GUANGWEN; ZHANG, LIYING
To: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
Reel/Frame 054220/0110 →
Continuity (5)
Division 14652324
Continuation In Part 12362847 · Jan 30, 2009
Provisional Application 61737616 · Dec 14, 2012
Provisional Application 61063288 · Jan 31, 2008
Related Publication 20190046577A1 · Feb 14, 2019